公开(公告)号：US20240254251A1

公开(公告)日：2024-08-01

申请号：US18598342

申请日：2024-03-07

申请人： Vor Biopharma Inc.

发明人： Anthony Boitano ,  Michael Cooke ,  Charlotte Fenton McDonagh ,  Rahul Palchaudhuri ,  Rajiv Panwar ,  Bradley R. Pearse ,  Paul Fredrick Widboom ,  Patricia Ann Cruite

IPC分类号： C07K16/28 ,  A61K35/12 ,  A61K35/28 ,  A61K39/00 ,  A61K47/68 ,  A61P35/02 ,  A61P37/06

CPC分类号： C07K16/289 ,  A61K35/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61P35/02 ,  A61P37/06 ,  A61K2035/124 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92

摘要： Disclosed are anti-CD45 antibodies, antigen binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. Such antibodies and ADCs are useful in therapeutic methods, including methods of depleting CD45+ cells from a patient. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy, and to improve the engraftment of hematopoietic stem cell transplants, by selectively depleting endogenous CD45+ cells prior to the transplant procedure.